Theranostics: Overview

Quick Answer

Theranostics pairs a diagnostic radiopharmaceutical (to see where a molecular target is expressed) with a therapeutic one that binds the same target to deliver radiation directly to disease. The same targeting molecule carries an imaging isotope for the scan and a cytotoxic isotope for treatment — so imaging both selects patients and confirms the target is present before therapy. The two established target–ligand systems in routine practice are PSMA (prostate cancer) and somatostatin receptors (neuroendocrine tumors); bone-seeking Ra-223 and liver-directed Y-90 are related radionuclide therapies.

Clinical Importance

Theranostics is the fastest-growing area of nuclear medicine and one of the fastest-growing in all of oncology. It has moved radionuclide therapy from a niche endocrine tool (I-131) into mainstream solid-tumor treatment, with randomized survival benefits in metastatic prostate cancer and neuroendocrine tumors, and a large industry pipeline of new targets and isotopes. Understanding the paradigm — target selection by imaging, dosing, dosimetry, and safety — is now core competency for nuclear medicine physicians.

The core paradigm

The defining principle is a shared molecular target. A ligand (small molecule, peptide, or antibody) that binds a target overexpressed on tumor cells is labeled either with a diagnostic isotope (a positron or gamma emitter, e.g. Ga-68, F-18, Cu-64) for PET/SPECT, or with a therapeutic isotope (a particle emitter, e.g. Lu-177 (β⁻) or Ac-225 (α)) for treatment. Because the biodistribution of the pair is nearly identical, the diagnostic scan predicts where the therapy will go — enabling true patient selection and post-therapy verification.

The established systems

Therapeutic isotopes — beta vs. alpha

• Beta emitters (Lu-177, Y-90, I-131): moderate-energy electrons with a tissue range of millimeters. The longer range gives a "crossfire" effect useful for bulkier or heterogeneous disease, at the cost of some dose to adjacent normal tissue. Lu-177 also emits imageable gammas, enabling post-therapy SPECT and dosimetry.
• Alpha emitters (Ra-223, Ac-225, Pb-212): very high-energy, short-range (micrometers) particles with high linear energy transfer, producing dense, largely irreparable DNA damage over a few cell diameters. Attractive for micrometastatic disease and radioresistant tumors; the challenge is managing daughter-nuclide redistribution and off-target toxicity (e.g. xerostomia with Ac-225-PSMA).

Choosing the therapeutic isotope

The isotope determines potency, range, imageability, and radiation-safety profile:

• Lu-177 (β⁻, t½ 6.65 d): millimeter range with "crossfire," plus an imageable gamma — every therapy cycle can double as a post-therapy SPECT/dosimetry scan. The workhorse for PSMA and DOTATATE.
• Y-90 (β⁻, t½ 2.7 d): higher-energy beta, longer range, pure beta (bremsstrahlung/PET only) — used for liver radioembolization.
• I-131 (β⁻ + penetrating γ): treats thyroid disease but the penetrating gamma raises radiation-safety/isolation demands.
• Ac-225 / Pb-212 (α): micrometer range, very high LET, potent against micrometastatic/radioresistant disease — investigational, with daughter-redistribution and supply challenges.

Lu-177's imageable gamma is a built-in advantage no pure-beta or alpha emitter shares: it lets you verify delivery and perform dosimetry from the treatment itself.

The shared workflow

Across systems the arc is the same: confirm target expression on the diagnostic scan → verify organ function → deliver therapy (usually outpatient for Lu-177/Ra-223) → post-therapy imaging/dosimetry where feasible → monitor labs and markers → reassess before each cycle → response assessment. The physician owns consent, toxicity, dosimetry, and longitudinal follow-up — not just the infusion.

Dosimetry and organs at risk

Fixed-activity regimens dominate approved practice (e.g. 7.4 GBq per cycle), but dosimetry-guided dosing can personalize therapy and is increasingly expected. The dose-limiting organs differ by agent: kidneys and salivary glands (PSMA), kidneys and marrow (DOTATATE), marrow (Ra-223), normal liver and lungs (Y-90).

Amino-acid co-infusion (arginine/lysine) reduces renal peptide reabsorption during DOTATATE therapy; hydration and, for Y-90, MAA-based lung-shunt assessment protect the relevant organs at risk. Cumulative marrow and renal dose across cycles is the practical constraint on the number of treatments.

High-Yield Pearls

• Imaging is the gatekeeper: therapy is only given when the diagnostic scan confirms adequate target expression (e.g. PSMA-avid disease, Krenning 3–4 uptake).
• Lu-177's imageable gamma allows post-therapy SPECT/CT to confirm delivery and perform dosimetry — a built-in quality check beta-only isotopes lack.
• Kidneys and salivary glands (PSMA) and kidneys and marrow (DOTATATE) are the key organs at risk.

Common Pitfalls

• Treating without confirming target positivity, or ignoring discordant disease (e.g. FDG-positive / PSMA-negative lesions predict poorer benefit).
• Underestimating the multidisciplinary and logistical demands (radiopharmacy supply, radiation safety, scheduling around isotope half-life).

Response Assessment

Response is judged with molecular-imaging-specific frameworks (RECIP 1.0 for PSMA, Krenning-based SSTR assessment), biochemical markers (PSA, chromogranin A), and conventional imaging. See the theranostics response-criteria page.

Self-Check

Key References

• Sartor O, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer (VISION). N Engl J Med. 2021.
• Strosberg J, et al. Phase 3 trial of ¹⁷⁷Lu-DOTATATE for midgut neuroendocrine tumors (NETTER-1). N Engl J Med. 2017.
• SNMMI/EANM practice guidelines for ¹⁷⁷Lu-PSMA and ¹⁷⁷Lu-DOTATATE radioligand therapy.